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In countries with advanced economies better health and hygiene conditions, along with
the introduction, in some cases, of global vaccination, have relegated most viral hepatitis
to marginal social groups and, in particular, drug users (DUs). The availability of safe and
effective vaccines for hepatitis A virus (HAV) and B (HBV)may play amajor role in combating
this phenomenon. Despite the availability of a safe and effective vaccine for over a decade
and the recommendations of international health organizations, vaccinations against HAV
among DUs are not as widely known and available as are HBV vaccinations. The purpose
of this review article is to present the most signiﬁcant data in the literature on the preva-
lence of HAV among DUs and the role of targeted vaccination. To our knowledge, the
present article is the ﬁrst to solely deal with vaccination against HAV in DUs. Immunization
after the administration of anti-HAV vaccine has been demonstrated in DUs even if they
have responded signiﬁcantly less than either the general population or carriers of chronic
liver disease. All the vaccines were well tolerated and adherence to the vaccine schedule
was good. Further studies are needed to optimize the timing and doses of vaccine to be
administered to DUs, especially to assess adherence and antibody persistence.Vaccination
campaigns are feasible among DUs and have proven to be highly cost–effective.
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INTRODUCTION
Addiction and diffusion of viral hepatitis are two different phe-
nomena but have long been closely correlated.Addiction is a global
phenomenon, with geographic location having relatively little to
do with its progress in a country, while there are large differences
in the spread of viral hepatitis as related to its progression in dif-
ferent countries. Such differences tend to decrease signiﬁcantly
among drug users (DUs; United Nations Ofﬁce on Drug, and
Crime, 2006; Aceijas et al., 2004). In drug-addicted patients, in
conjunction with the decrease of HIV-rate mortality, death from
liver diseases have signiﬁcantly increased (EMCDDA, 2003; Schae-
fer and Mauss, 2008). Counteracting this spread is a priority task,
which has to involve all the structures that can interact with drug
abusers.
Hepatitis C virus (HCV) is surely the most important hepatitis
among DUs regarding both its diffusion and its high percentage of
chronic disease. Currently, it is the most common cause of chronic
hepatitis in developed countries (Centers for Diseases Control and
Prevention, 2002; Schaefer and Mauss, 2008).
Health education and harm reduction policies (i.e.,methadone
or buprenorphine maintenance therapies and needle-exchange
programs) are at the moment the only measure of prevention
of HCV, since there is neither speciﬁc vaccination nor effective
prophylaxis against exposure. Interventions using strategies that
Abbreviations: CLD, chronic liver disease; DUs, drug users; GPOP, general popula-
tion; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV,
hepatitis D virus.
combined substance-use treatment and support for safe injection
were most effective at reducing HCV seroconversion (Hagan et al.,
2011).Vaccination campaigns targeted at high-risk groups and the
introduction of mass vaccination in almost all developed countries
has signiﬁcantly reduced HBV prevalence among the youngest
DUs (Baral et al., 2007; Brim et al., 2007). HBV infection through
sexual transmission has an important role among non-injective
DUs (Gyarmath et al., 2002; Rich et al., 2006).
HepatitisDvirus (HDV) is causedby adefectiveRNA-virus that
requires the presence of theHBVSurfaceAntigen for transmission.
HDV can be acquired both as a co-infection with HBV and as an
overlap in a chronic HBV carrier. HDV infection can be effec-
tively prevented with vaccination against HBV, while protection
does not exist for chronic HBV carriers. In Europe and in the USA
HDV infection has almost disappeared in the general population
(GPOP), remaining conﬁned almost entirely to DUs (Gaeta et al.,
2000; Farci, 2003). Hepatitis A virus (HAV), the causative agent of
type A viral hepatitis, is an ancient picornavirus virus, which was
identiﬁed almost 40 years ago. Each year HAV affects 1.5 million
people worldwide. The geography of infection is tightly linked to
the quality of sewage water depuration systems. Improved living
conditions and subsequent changes in HAV epidemiology have
decreased the disease burden of hepatitis A in most developed
countries (Martin and Lemon, 2006; Koslap-petraco et al., 2008;
Jacobsen and Wiersma, 2010). The clinical manifestations of HAV
infection range from asymptomatic to fulminant hepatitis. The
severity of the disease is strongly dependent on the age of the
host, being the asymptomatic disease typical of childhood while,
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in adults, HAV infection causes severe manifestation of liver dis-
ease in 80%of cases.HAV rarely causes fulminant hepatic failure in
the GPOP, generally less than 0.5% of cases (Crowcroft et al., 2001;
Koslap-petraco et al., 2008; Jeong and Lee, 2010). Yet it is a cause
of signiﬁcant morbidity and mortality in patients with chronic
liver disease (CLD). The pathogenesis of acute liver damage is
thought to be mediated by host cytotoxic T-lymphocytes directed
against virus-infected hepatocytes (Vento et al., 1998; Locarnini,
2000; Saab et al., 2005). Acute HAV super infection in carriers of
chronic hepatitis C has been associated with a particularly high
mortality rate, dozens of times higher than HAV infection in the
GPOP (WHO, 2000; Keeffe, 2006; Kumar and Herrera, 2010).
Despite the recommendations of all the most important inter-
national public health associations and the existence of several
scientiﬁc works that conﬁrm the validity of such recommenda-
tions, HAV vaccination in DUs is still far too low (Brook, 2002;
Quaglio et al., 2006b; Baral et al., 2007; Brim et al., 2007; Buxton
and Kim, 2008; Lugoboni et al., 2009).
OBJECTIVES
The PubMed and Google Scholar database were searched for rele-
vant publications between 1995 and 2010using the followingmed-
ical subject heading (MeSH) terms: “immunization,” “immuno-
genic,” “reactogenicity,” “immunogenicity,” “outbreak,” “vaccine,”
“vaccination,”“hepatitisA,”“HAV infection,”and“adherence.”The
MeSH terms were cross-referenced with articles containing the
following keywords: “drug use,” “DUs,” “IDU,” “substance abuse,”
“heroin dependence,” “addiction,” “intravenous”: 84 potentially
relevant studies were found. Thirteen studies evaluating epidemi-
ological data and other ﬁve studies assessing vaccination strategies
in DUs using epidemiological tools were retrieved. Only three
studies evaluating seroconversion after vaccination were found.
Four reviews were identiﬁed.
This is the ﬁrst review full dedicated to the problem of HAV
among DUs and to the speciﬁc prophylaxis with vaccination in
this risk group.
The aims of the present paper were to review current literature
regarding:
(a) epidemiology of HAV among DUs
(b) the efﬁcacy, coverage, safety, and acceptance of HAV vaccine
in DUs
(c) the role of co-infections on HAV vaccine
(d) targeted strategies (combined vaccinations, experimental
schedules, emergency strategies).
HAV AND DRUG USERS
Even if HAV infection seems to be declining in much of the world
as a result of better hygienic conditions, positive serology among
DUs in non-endemic countries was reported as much higher than
in the GPOP (Table 1).
Drug users are at risk of contracting the infection for at least
three reasons: route of infection, by injection and sex, poor hous-
ing conditions, and the higher probability of being jailed. Possible
HAV infection can have high clinical severity because of the fre-
quent presence of chronic HCV infection, often being worsened
by alcohol abuse.
ROUTE OF INFECTION
If fecal–oral contamination is by far the commonest way of trans-
mission, it is possible to transmit the virus by injection, sexually
(most of all, throughoral–anal sex), and through vertical transmis-
sion (Brook, 2002; Martin and Lemon, 2006; Jeong and Lee, 2010).
In a recent study, HAV viremia persisted for an average of 79 days
after the liver enzyme peak. In addition, HAV-RNA was detected
several days before IgM antibodies to HAV were detected. These
results indicate that adults with HAV infection are viremic for as
long as 30 days before the onset of symptoms and that the duration
of viremia may be longer than previously described, suggesting
that the opportunity for transmission may be greater than previ-
ously suspected (Bower et al., 2000; Crowcroft, 2003). Outbreaks,
where it was possible to genetically demonstrate a common origin,
have been repeatedly reported among DUs in non-endemic coun-
tries such as Norway, Holland, Great Britain, Italy, and the USA
(Stene-Johansen et al., 1998; Hutin et al., 2000; O’Donovan et al.,
2001; Granerød and Crowcroft, 2002; Syed et al., 2003; Roy et al.,
2004; Spada et al., 2005; Tjon et al., 2005). Particularly, during an
HAV outbreak among DUs in central Italy in 2002,mortality from
hepatic failure was 6.4% compared to a national average of 0.01%
(Spada et al., 2005). In such cases the role of mixed-use syringes
can be crucial. By capture–recapture analysis, the suspicion has
been reported that in England underreporting of HAV infection
may be high and a number of outbreaks have occurred undetected
by routine surveillance (Matin et al., 2006). Seroprevalence data
indicate that, in non-endemic countries for HAV, positive levels
among DUs are generally higher than among the GPOP (Table 1),
even if there are some exceptions; in the areas, where there are data
of lower social marginality among DUs (Quaglio et al., 2006a),
the HAV seroprevalence among DUs and GPOP does not differ
(Lugoboni et al., 2005).
LIVING CONDITIONS
Even if increasingly effective water sanitation and policies for tar-
geted vaccination, in themost developed countries,havedrastically
reduced HAV incidence – between 1995 and 2007 the rate of acute
hepatitis A was reduced by 92% in the United States (Daniels
et al., 2009),HAV outbreaks have been frequently reported among
the homeless. The homeless have an increased risk of HAV infec-
tion due to living conditions when compared with the GPOP
(Tjon et al., 2005; Hagan et al., 2011). This increased risk has
been demonstrated to be related to homelessness, independently
of other known risk factors, such as injection of illicit drugs, sexual
habits, and ethnicity (Hennessey et al., 2009). In fact, a recent study
on HAV infection among DUs found that it was associated with
low educational level and low-hygienic variables, factors found to
be more decisive than needle-exchange (Luquero et al., 2009).
THE PRISON EXPERIENCE
Probably associated with many risk behaviors (common use of
drugs by injection, anal sex, high presence of subjects coming from
high HAV endemicity) or with crowded living conditions, prisons
have been described many times as situations of high-risk for HAV
infection even in the developed countries with low endemicity for
HAV (Skidmore et al., 2001). Jail and facility incarcerations were
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Table 1 | Hepatitis A virus: sero-epidemiological data among DUs.
Citation (country) Population SPr (%) Route of infection Mainly comments
Ochnio et al. (2001) (CAN) DUs 42.6 IDU/MSM Vulnerability to HAV outbreaks
Lugoboni et al. (2005) (I) MMT/DUs 28.7 IDU/nIDU Prevalence similar than the GPOP
Wells et al. (2006) (USA) Dus 33 LC DUs are targets for vaccination
Gerlich et al. (2006) (CH) Dus 41.2 IDU Need of vaccination
Latimer et al. (2007) (USA) Jail DUs 36.9 JI Vaccination within CF
Reimer et al. (2007) (D) Dus 57.7 IDU/LC Need for outreach vaccination programs
Poulos et al. (2007) (AUS) DUs/HLs 48 – Potential beneﬁt from HAV vaccination
Campbell et al. (2007) (USA) DUs 19 IDU Low coverage with vaccination
Bart et al. (2008) (USA) MMT 46.1 – DUs pose a public health risk
Sunthornchart et al. (2008) (T) DUs 60.1 IDU Vaccination need
Luquero et al. (2009) (E) Dus 35.5 LC Vaccination recommended
Hennessey et al. (2009) (USA) DUs/HLs 52 LC HAV vaccine for homeless
Ramasamy et al. (2010) (AUS) MMT 49 – Further studies are needed
Removille et al. (2011) (L) DUs 57.1 IDU/nIDU Need for new immunization strategies
DUs, illicit drug users; HLs, homeless; MMT, methadone maintenance treatment; CF, correctional facility; SPr, seroprevalence; IDU, injecting drug use; nIDU,
non-injecting drug use; LC, living conditions; MSM, men who have sex with men; JI, jail incarceration.
each independently associated with high HAV prevalence among
DUs (Latimer et al., 2007; Reimer et al., 2007).
THE STATE OF CHRONIC LIVER DISEASE
The levels of prevalence of HCV antibodies are reported to be
extremely high in all geographic areas; they are almost all over
70%, with few exceptions (United Nations Ofﬁce on Drug, and
Crime, 2006; Aceijas et al., 2004; Baral et al., 2007). We believe
that the distinction between injective or non-injective use of illicit
drugs is often limited: it is often hard to distinguish the manner
of consumption even in the same subject; moreover, in a subject
that had never used drugs by injecting, the risk of contracting
typical injecting hepatitis has been demonstrated to be very high
(Gyarmathy et al., 2002; Quaglio et al., 2003). It is most of all the
carrier state of HCV (because of the high tendency of this virus to
being chronic) to make DUs particularly at risk for the acute form
of high lethality hepatitis A.
HEPATITIS A VACCINATION
For all these reasons both the WHO and the American Associ-
ation for the Study of Liver Diseases have recommended HAV
vaccine for people using illicit drugs,with orwithout chronicHCV
infection. Furthermore, WHO recommends HAV vaccination for
individuals with chronic HCV infection without specifying a dif-
ferent dose or schedule. The United States Advisory Committee
on Immunization Practices cites a lack of evidence for anti-HAV
vaccine administration on the basis of chronic HCV alone, but
recommends that HAV-susceptible people with evidence of CLD
or who are awaiting liver transplants, should be vaccinated (WHO,
2000; Crowcroft et al., 2001; Buxton and Kim, 2008).
Two effective vaccines have been available since 1995.
The former vaccination schedule for HAV consisted of 770
units; initially in three different doses, at 0, 1, 6months. It has been
made more rapid to meet the needs of travelers to exotic coun-
tries, who are the major purchasers of this vaccine. More recently,
after an increased dose of vaccine (1440 units) was demonstrated
to be effective after 1month in almost all healthy young adults,
a second dose of vaccine is proposed after a variable time of 6–
18months to get a longer-lasting vaccine coverage, since a lasting
protection after the disappearance of speciﬁc antibody titer has
not been demonstrated in HAV vaccination (in contrast to HBV
vaccination; Andre et al., 2002; Baral et al., 2007). Such vaccina-
tion schedules have been demonstrated to be largely effective in
seroconversion among the GPOP and adequate antibody levels
were found after many years of vaccination, far beyond expecta-
tions. Vaccine-induced antibodies persist for more than 12 years
in adults and there is good mathematical evidence that antibodies
can persist for more than 25 years in more than 95% of vaccines
(Nothdurft, 2008). Primary HAV vaccination failure in a healthy
population has to be considered a rare event (Bonanni et al., 2005).
Seroconversion after HAV vaccination has been deﬁned by a par-
ticular neutralizing antibody level more than 20mIU/mL. The
immunogenicity of vaccine function has generally been identi-
ﬁed by titring antibody levels. Even if recent studies have stressed
the role of the cell-mediated immune response, in the protection
against HAV infection the humorally mediated response, in the
form of neutralizing antibodies, plays the main role (Baral et al.,
2007; Nothdurft, 2008). Scientiﬁc literature reports a number of
signiﬁcant data onHAVvaccine coverage in the patients withCLD,
most of all in HCV-carriers, regardless of their addictive status.
Even if sub-optimal response to vaccines has been reported in
patients with CLD, more recent data seem to conﬁrm that in the
patients with CLD, the vaccine response to HAV vaccination is
better than the response to the HBV one. The response in terms of
seroconversion appears to be conditioned by the degree of ﬁbro-
sis and by diabetes (Saab et al., 2005; Keeffe, 2006; Buxton and
Kim, 2008; Kramer et al., 2009; Lugoboni et al., 2009). Generally,
after two doses of HAV vaccine, seroconversion was achieved in
a proportion between 75 and 98% of patients with CLD (Buxton
and Kim, 2008; de Artaza Varaza et al., 2009; Kramer et al., 2009).
Furthermore, there is a good level of evidence that the adminis-
tration of three doses of combined HAV–HBV vaccine gives better
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results even in the patients with advanced liver ﬁbrosis (de Artaza
Varaza et al., 2009; Kramer et al., 2009). However, it is not known
towhat extent the lower geometricmean anti-HAV concentrations
demonstrated after vaccination in individuals with HCV is trans-
lated into a shorter duration of protection against HAV (Buxton
and Kim, 2008).
Despite the encouraging responses in terms of immune
response, the lack of serious side effects and cost–effectiveness, the
supply, and the cover of HAVvaccine among patientswithCLDare
still sub-optimal (Shim et al., 2005; Daryani et al., 2007; Hernan-
dez et al., 2009). Unlike HBV, where there are studies focused on
DUs, to date there are still few studies that have evaluated HAV
vaccination among DUs. After HBV vaccination, sub-optimal
immunological responses (58–77%) have been reported among
DUs despite the 95–99% proven in young adults from the GPOP
(Baral et al., 2007; Brim et al., 2007).
HAV TARGETED TO DUs
In the literature, there are three types of studies on the validity
of protection for HAV among DUs: the ones that have evaluated
the response in terms of seroconversion and/or immunogenic-
ity (also to predict the durability) of HAV vaccination, the ones
that have evaluated the immune response after administration of
HAV–HBV combined vaccination and the ones that have evalu-
ated the effective protection in non-traditional settings such as
accelerated vaccination campaigns during outbreaks of HAV and
immunization blitz delivered to high-risk inner-city populations.
OFFER, COVERAGE, AND COMPLIANCE OF THE VACCINE FOR HAV
Hepatitis A virus vaccines have been widely shown to be safe, both
the monovalent ones and the HAV–HBV combined ones. DU vac-
cination poses quite speciﬁc problems related not only to efﬁcacy
but also to supply and to compliance. There are very few studies
that have evaluated these factors. The baseline study on supply and
coverage of DUs with the HAV vaccine in addition to that for HBV,
was performed in the USA and it evaluated more than 3000 DUs
in ﬁve different cities. Although 83% of participants were will-
ing to be vaccinated, only 36% of them received at least one dose
of vaccine; coverage rate varied greatly from Baltimore (83%) to
Chicago (2%). Adherence was highest when vaccine was available
immediately on-site and lowest when offered only after receiving
serological results. Monetary incentives bettered adherence when
on-site vaccination was not available (Campbell et al., 2007). In
a Swiss study that evaluated the HAV and HBV vaccination cov-
erage in patients entering the heroin-assisted treatment between
2000 and 2002, only 10.3% of subjects received the vaccine despite
the fact that 48.5% were susceptible to HAV (Gerlich et al., 2006).
Four other studies focusing onHAVvaccine compliance among
DUswere found. Two groups performed the studies, the ﬁrst (mul-
ticenter trial) in the northeast of Italy, and the second in Los
Angeles, CA (USA). Both groups studied DU compliance with
HAV vaccine and HBV as well. Many conclusions are similar, in
the four studies, for the two vaccines. A good addiction therapy
oftenmeans a good adherence to the vaccination programs.Multi-
disciplinary involvement by all the professionals of the services has
proven successful in obtaining a good adherence to vaccination.
Nurses have proven to be crucial in improving the acceptance and
the adherence to vaccination in all the studies (Nyamathi et al.,
2010a,b).
Programs designed for homeless DUs should include malleable
psychosocial and health belief model variables; these aspects pro-
vide leverage points for interventions such as vaccine adherence
(Stein and Nyamathi, 2010).
The vaccination programs directly charged by the services
involved in the treatment of addiction are boast a lower drop-out
rate. This aspect, strongly demonstrated in the biggest study that
has evaluated compliance with vaccination among DUs (Quaglio
et al., 2002, 2004b), seems to also be a crucial point in HAV vac-
cination, although assessed in a much smaller number of subjects
(Quaglio et al., 2004a), and it has demonstrated a good adher-
ence even to a more complex vaccination schedule as it is that
of the HAV–HBV combine vaccine. The Addiction Services that
vaccinate less are those with the worst results in terms of adher-
ence to the programs (Quaglio et al., 2006a). Offering serologic
screening in the absence of a concrete possibility of vaccination is
inappropriate and illogical (Quaglio et al., 2006a). Rapid sched-
ules, especially with combined HAV–HBV combined vaccine (0, 1,
2, 52weeks), help in limiting the drop-out rate, but they have not
been studied in terms of efﬁcacy among DUs (Buxton and Kim,
2008).
Relying on the description that the DUs make of their serologi-
cal hepatitis state is a source of error; in low threshold services, the
following policy is recommended: "Don’t ask, take a blood sample,
give a dose of vaccine, and try to schedule another visit" (Kuo et al.,
2004; Quaglio et al., 2006a; de La Fuente et al., 2007), but in the
more structured services, it is more rational to keep an efﬁcient
data report to get the best solutions (Quaglio et al., 2004a; Lugob-
oni et al., 2009). Needle-exchange projects have proven effective in
places that offer HBV vaccination and it is reasonable that it is the
same thing for HAV vaccine (Des Jarlais et al., 2001; Altice et al.,
2005). Prison facilities are other places that have a great opportu-
nity to offer vaccination (Weinbaum et al., 2003). The difﬁculty
of administering both doses of vaccine should not be discouraged
from starting vaccination. There is not any risk to administering
additional doses of vaccine (Quaglio et al., 2006a). Furthermore,
immunizations delivered to high-risk inner-city populations in a
blitz format can be successfully delivered (Weatherill et al., 2004).
REACTOGENICITY AND IMMUNOGENICITY OF MONOVALENT VACCINE
AMONG DUs
Currently in the literature there are only two experimental stud-
ies that have evaluated such variables among DUs, both of them
are multicenter studies conducted by Addiction Clinics in north-
ern Italy. As already mentioned in the case of HBV vaccine, the
response to the HAV vaccine has proved much weaker among
DUs than among healthy adults. In the ﬁrst study, which evaluated
only seroconversion without calculating the geometric mean titer,
only 60% of subjects (all HCV positive, HIV negative) showed
seroconversion (HAV antibodies >20mIU/L) after the ﬁrst dose,
while after the second dose all the subjects reached a protective
antibody titer (Lugoboni et al., 2000).
In the second study, which consisted of dosing post-vaccine
antibody concentration, in 36% of patients there was no serocon-
version after the ﬁrst dose and, even if after the second dose in
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100% (43 on 43) of patients there was seroconversion, the anti-
body titer proved very low and short-lasting. The authors of both
studies concluded by recommending administering the booster-
dose after no more than 6months from the ﬁrst one because of the
initial weak response among DUs. The HAV vaccination schedule
currently proposed also for DUs proved ineffective because it has
been studied only in the GPOP, where the ﬁrst dose of vaccine led
to seroconversion in almost all cases and where the booster-dose
is required only to ensure lasting protection over time (Nothdurft,
2008; Kramer et al., 2009). Further studies are therefore required
to optimize the timing and the doses to utilize among DUs to get
adequate results.
There are different causes that explain this weak response to
vaccination among DUs: immunity dysfunction, alcohol abuse,
polydrug abuse,multiple bacterial infections,HCV infection,mal-
nutrition, and cigaret smoking (Lemon and Thomas, 1997;WHO,
2000; Baral et al., 2007; Buxton and Kim, 2008).
Smoking status can be relevant because tobacco consumption
is extremely prevalent among DUs and methadone-maintained
patients but, despite this fact, substance abuse treatment programs
too often ignore tobacco use (Baca and Yahne, 2008). All these
factors should also be evaluated in the case of HAV vaccination
for a better comprehension of immunogenicity and reactogenicity
among DUs and for the development, if necessary, of a speciﬁc
vaccine schedule.
HAV VACCINATION IN HIV-INFECTED PATIENTS
Hepatitis A virus vaccination is strongly recommended for HIV-
infected patients, especially those with HCV co-infection or with
CLD. An impaired immunogenicity of vaccines, including HAV
vaccination, has been reported in patients with HIV infection
(Baral et al., 2007). DUs are universally considered at high-risk
of HIV infection, consequently immunological response of HAV
vaccination is a relevant issue to consider.
The factor associated with better reactogenicity is the suppres-
sion of HIV replication at time of vaccination. A low viral load
has been also associated with durable HAV response. There is less
consent about the role of CD4 count and gender (Laurence, 2005;
Weissman et al., 2006; Overton et al., 2007; Crum-Cianﬂone et al.,
2011).
A schedule of vaccination with three doses of vaccine has
been demonstrated more effective in HIV-infected adults (Crum-
Cianﬂone et al., 2011).
However, no study evaluating the immunologic response
among DUs with HIV has been found in the literature.
In all studies considered HAV vaccination has come out safe in
HIV carriers.
COMBINED HAV–HBV VACCINATION
Since 1996 a combined vaccination against both viral forms has
been marketed beyond the normal monovalent vaccines; it has
been proposed with a schedule at 0, 1, 6months and it has been
demonstrated to be safe among theGPOP (Joines et al., 2001; Brim
et al., 2007). As mentioned before, the vaccine gave better results, if
compared tomonovalent vaccine,amongpatientswithCLD.Good
tolerability and immunogenicity have prompted frequent trials
aimed at reducing the administered doses and at accelerating the
vaccination times (Beran et al., 2010; Burgess et al., 2010). Various
accelerated schedules of combined vaccine have been proposed,
generally targeted to last-minute travelers and, in some cases, to
short-term correctional facility inmates.
This promising vaccine had been studied only once among
DUs and it had been demonstrated to be well tolerated; the DUs
study participants, however, responded with antibody levels sig-
niﬁcantly lower than that reported for the GPOP, even if, by the
end of the study, all the DUs had developed a protective level. It
must be emphasized that the antibody response to HAV was sig-
niﬁcantly greater than that found in DUs that had been vaccinated
with monovalent vaccines: the combination of two antigens could
therefore have an adjuvant effect as already reported in patients
with CLD (Lugoboni et al., 2004; de Artaza Varaza et al., 2009).
EMERGENCY VACCINATION DURING OUTBREAKS
Many outbreaks of HAV involving DUs have been described.
Although there have been no prospective observational studies
evaluating clinical protection from HAV, four ecological studies
have demonstrated thatDUs,when vaccinated during an outbreak,
retain the ability to mount protective immunological responses
even after a single dose of vaccine.
The ﬁrst experience of rapid vaccination of high-risk subjects
(DUs and homeless) was performed in Bristol (United Kingdom)
during an outbreak that involved a total of 123 subjects, most
of whom were DUs and homeless. The strategy was described
as effective in preventing further spread of infection (Syed et al.,
2003).
In Rotterdam (the Netherlands), in 2004, there was an outbreak
of HAV involving 30 homeless DUs. Contact tracing appeared
very difﬁcult in such a hard-to-reach group, so a mass vaccina-
tion campaign was performed over a 2-week period resulting in
a single dose HAV vaccination. The immunization involved more
than 1500 DUs and was effective in stopping the outbreak (Tjon
et al., 2005). Other studies demonstrated that targeted vaccination
campaigns,performedamongDUs in all facilities,were able tomit-
igate a community-wide HAV epidemic (Gilbert et al., 2004) and
an outbreak of HAV developed among prison inmates (Thorburn
et al., 2001; Table 2).
THE COST–EFFECTIVENESS OF VACCINATION AGAINST HAV
Hepatitis B virus vaccination has proven to be extremely advanta-
geous in terms of cost–beneﬁts (Buxton and Kim, 2008; Lugoboni
et al., 2009). There are no studies that have evaluated the cost–
effectiveness of selective HAV vaccination among DUs as com-
pared to other intervention models. Since most DUs are HCV
infection carriers we will extrapolate some estimates made for
this category of persons. Recent studies have evaluated the cost–
effectiveness of twodifferent vaccination strategies in patientswith
HCV: selective HAV vaccination and universal HAV–HBV com-
bined vaccination. The selective HAV vaccination strategy proved
to be themost cost–effective; however, the universal strategywould
become more effective, thus it may be worth the additional cost
(Weatherill et al., 2004; Jakiche et al., 2007).
However vaccination programs should be adapted to regional
situations, according to differing epidemiology and disease
burdens.
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Table 2 | Hepatitis A virus vaccine among DUs.
Citation Study population Rewards/safety Schedule Maily comments
TRADITIONAL SCHEDULE: MONOVALENTANTI-HAVVACCINE
Lugoboni et al. (2000) MMT, NE Italy No/safe 0, 6months Sub-optimal response
Quaglio et al. (2004a) MMT, ACs, NE Italy No/safe 0, 6months Sub-optimal response
Civitelli (unpublished data)* MMT, BMT, NE Italy No/safe 0, 6months Seroconversion rate 96.8%
TRADITIONAL SCHEDULE: COMBINEDANTI-A/BVACCINE
Lugoboni et al. (2004) MMT, BMT, ACs, NE Italy No/safe 0, 1, 6months Effective
ACCELERATED SCHEDULE FOR OUTBREAK CONTROL; MONOVALENT HAVVACCINE
Thorburn et al. (2001) Injailed DUs, ACs No/safe Single dose Ecological, partial effective
Syed et al. (2003) DUs and homeless No/NS Single dose Ecological, effective
Gilbert et al. (2004) Injailed DUs No/safe Single dose Ecological, effective
Tjon et al. (2005) DUs No/NS Single dose Ecological, highly effective
Weatherill et al. (2004) DUs and homeless No/NS Single dose Ecological, effective
MMT, methadone maintenance treatment; NE Italy, northeast Italy; ACs, addiction clinics; BMT, buprenorphine maintenance treatment; DUs, illicit drug users; NS,
not stated. *Unpublished data.
DISCUSSION
In developed countries, acute viral hepatitis decreased in the
last decade. In the US, the acute HAV incidence was reduced
by 92%, from 12 cases per 100,000 inhabitants in 1995 to
1 case in 2007, the lowest rate ever recorded (Daniels et al.,
2009). In developed countries, HAV infection occurs in adult-
hood rather than in childhood. These changes may paradoxi-
cally enhance the disease burden, because the infection acquired
during childhood can be largely asymptomatic while the oppo-
site happens in adulthood. The increase in prevalence in young
adults coincides with behavioral-related risk factors and disease
importation.
Travel to high-risk areas in young people was associated with a
signiﬁcant increased risk of HAV infection (Diez Redondo et al.,
2009). These aspects have a wide validity but they become crucial
when DUs are considered. HAV rarely causes fulminant hepatic
failure in the GPOP, but it is a cause of signiﬁcant morbidity
and mortality in subjects with CLD, a condition involving most
DUs. Viral hepatitis is not the inevitable result. The availability
of safe and effective vaccines for HAV and HBV can play a major
role in stemming the phenomenon. The two vaccinations have
partially different objectives and strategies and they ﬁnd marked
differences in attention and availability in the specialist facili-
ties. HAV vaccination is less widely known and available than
HBV vaccination, despite no lack of recommendations of interna-
tional health organizations to vaccinate subjects at risk (Klevens
et al., 2010). The low percentage of vaccinated DUs recognizes two
causes: the absence of vaccination programs designed speciﬁcally
for DUs and the low number of health workers able to vaccinate
the DUs (François et al., 2002; van Steenbergen, 2002; Perrett et al.,
2003).
There is good evidence that combined HAV/HBV vaccines have
better immunogenicity than monovalent ones. However, many
countries now immunize infants and/or adolescents against HBV
and this raises the question whether to also immunize DUs with
combined vaccine who had previously received HBV vaccine at
an earlier age. At present, we do not really know if HBV vaccina-
tion received during adolescence and, even more, during infancy
can protect these individuals once they become DUs. The lack of
studies on this question is certainly a gap that should be ﬁlled.
Prevention of viral hepatitis among DUs may actually limit the
spread of these diseases, not only in these subjects, but also in their
relatives and in the health workers who deal with DUs. There is a
clear need for deﬁnitive studies of vaccination strategies inDUs.As
noted by other authors, there is a precise and disturbing ﬁnding
in reviewing the scientiﬁc literature on vaccination in DUs: this
group is at high-risk for vaccine-preventable hepatitis but it com-
monly receives the lowest immunization. This lack of attention
occurs at all levels: not only in the management of clinical cases
but also in terms of scientiﬁc speculation. It is hard to imagine
other situations where live unanimous recommendations to vac-
cinate and a paucity of data, especially when applied to the speciﬁc
group of DUs. Another paradox is that all the schedules of hepati-
tis vaccination are studied in young adults of the GPOP,whereas it
has now been clear for at least 20 years that DUs respond very dif-
ferently to immunization and the reasons for which this happens
are not yet completely understood. People who have researched in
the ﬁeld of addiction know that DUs are not the ideal subjects on
which to perform research and this is probably one of the reasons
behind the lack of data in the literature. It is therefore crucial that
more and more basic research on these topics be ongoing and that
this research be possibly managed by the same health workers that
offer and administer the hepatitis vaccinations to the DUs on a
daily basis.
KEY LEARNING OBJECTIVES
1. HAV infection seems to be declining in much of the world, but
the seroprevalence among DUs in non-endemic countries was
reported as much higher than in the GPOP.
2. HAV outbreaks are still occasionally reported in low-endemic
countries among inmates and inner-city high-risk populations.
3. Rapid immunization campaigns among DUs have been proved
to be effective during HAV outbreaks.
4. Even if DUs are less responsive than the GPOP to HAV
vaccination, as they are to HBV, it is feasible, safe, and
immunogenic.
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5. Vaccination programs with minor drop-out rates come to be
those administered directly by addiction clinics personnel.
6. Vaccinating DUs, ﬁnally, is cost–effective.
7. A better understanding of immunizations among DUs may
be crucial in the near future when, hopefully, anti-HCV and
anti-HIV vaccines will be available.
FUTURE RESEARCH ISSUES
1. No study has ever been made on the duration of HAV antibody
protection among DUs.
2. Even if studies have shown that persons with HIV respond less
well to a ﬁrst dose of HAVvaccination but fairly well to a second
one, no study has ever been made to evaluate the immunologic
response among DUs with HIV.
3. There is a clear need for more appropriate sched-
ules for the DUs to be studied, especially the rapid
schedules and the combined HAV–HBV vaccinations, that
proved to have better immunogenicity than monovalent
vaccines.
4. The co-factors associated to drug abuse should be studied more
thoroughly.
5. The question of whether to also immunize DUs with combined
vaccine who previously received HBV vaccine at an earlier age
has not yet been answered.
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